<div>
                                <figure class="article-image__container">
                                    
                                    
                                    
                                    <img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/PT-2-18-11-2025-shutterstock_2309849697-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="430" height="241" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2025/11/PT-2-18-11-2025-shutterstock_2309849697-430x241.jpg"/>
                                    
                                    <figcaption>Halozyme owns proprietary enzyme rHuPH20, underpinning Enhanze, a solution for rapid subcutaneous drug delivery. Credit: SaiArLawKa2/Shutterstock.com.</figcaption>
                                </figure>
                            </div>
                                             
     
<p>Merus and Halozyme have signed a worldwide non-exclusive partnership and licence agreement for subcutaneous formulation of petosemtamab.</p>



<p>The agreement involves the development and commercialisation of the administration of petosemtamab, an epidermal growth factor receptor (EGFR) times leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) bispecific antibody, using Enhanze drug delivery technology.</p><div>
<div id="div-gpt-ad-6065588-4"></div>
  
</div><div><div>
                   <div><h3>Go deeper with GlobalData</h3><ul><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - Lemzoparlimab in Marginal Zone B-cell Lymphoma </h4></div> </li><li><div><figure><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></figure></div><div><div>Reports 
                                                                
                                                                    
                                                                    
                                                                
                                                            </div><h4>LOA and PTSR Model - Lemzoparlimab in Peritoneal Cancer </h4></div> </li></ul> <div>
                    <h5>
                                                Go deeper with GlobalData
                                            </h5>
                    <p>
                        The gold standard of business intelligence.
                    </p>
                    <p>
                            Find out more
                            
                                
                            
                        
                    </p>
                </div>
                </div></div><section><figure><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></figure><h4> Discover B2B Marketing That Performs </h4><p>
						Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
					</p><p>
							Find out more </p></section></div>



<p>Merus licensed Halozyme’s Enhanze technology to accelerate advancement for the subcutaneous administration.</p><div id="slot-one"></div><div id="Sgpollsputhere"></div>



<p>Halozyme will receive an upfront fee, additional payments linked to commercial milestones and sales success from Meru, and low to mid single-digit royalties on net sales of petosemtamab formulated with the technology during the royalty period.</p>



<p>Merus chief operating officer and general counsel Peter Silverman stated: “Petosemtamab continues to show encouraging results in the clinical studies across numerous solid tumour cancers and has the potential to become a first and best in class treatment in head and neck cancer and beyond.</p>



<p>“We are proud to collaborate with Halozyme and look forward to working closely with their team on a subcutaneous administration.”</p><div> 
                         <div>


            <div>

                <img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/>
            </div>


            <div>

                <span class="gdm-company-profile-unit__form-excerpt">GlobalData Strategic Intelligence</span>
 <div id="gdm-form-wrapper">



                    <h1>
                        US Tariffs are shifting - will you react or anticipate?
                    </h1>
                    <p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
                    <span class="gdm-company-profile-unit__text">By GlobalData</span>
                
          </div>
          </div>  
           </div> Learn more about Strategic Intelligence</div>



<p>Halozyme president and CEO Dr Helen Torley stated: “We are excited to collaborate with Merus to advance treatment options for patients with r/m HNSCC and other potential indications.</p>



<p>“This collaboration represents a new opportunity for our Enhanze technology to improve treatment efficiency and enhance the patient treatment experience. Together, we aim to accelerate innovation for patients and healthcare providers.”</p><div id="slot-two"></div>



<p>Halozyme owns the enzyme rHuPH20 which underpins Enhanze, a solution enabling rapid subcutaneous drug delivery to lessen the treatment burden on patients.</p>



<p>The Enhanze technology has been licensed by companies including Takeda, Roche, Janssen, Pfizer and AbbVie.</p>



<p>In September 2025, Genmab signed an agreement to buy all shares of Merus at $97 per share, in an all-cash transaction valued at $8bn, boosting its oncology pipeline.</p>
<div id="slot-three"></div><p></p>



<div>
    
</div>



                   
               <div>
                 <h2>Pharmaceutical Technology Excellence Awards - The Benefits of Entering</h2>
                 <p>Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today!</p>
Nominate Now

             </div>

HALO

MRUS

<p>Merus and Halozyme have entered a worldwide non-exclusive partnership and license agreement for the subcutaneous formulation of petosemtamab. The collaboration involves using Halozyme's Enhanze technology to enhance the delivery of petosemtamab, an EGFR x LGR5 bispecific antibody. Halozyme will receive upfront fees, milestone payments, and royalties. The partnership aims to improve treatment options for various cancers, including head and neck cancer. Both companies express optimism about the potential benefits for patients and healthcare providers.</p>

Merus and Halozyme link on subcutaneous petosemtamab